脑钠肽与氨基末端-脑钠肽前体在急性缺血性脑卒中的相关研究进展

董 晓磊, 石 秋艳, 王 翠兰, 赵 名扬
华北理工大学

摘要

心源性卒中（Cardioembolism，CE）是缺血性脑卒中亚型之一，其病情通常较为严重，具有更高的死亡率，早期及晚期的复发率也更高。心房颤动（Atrial Fibrillation，AF）是心源性卒中的主要病因之一，而脑钠肽（Brain Natriuretic Peptide，BNP）是由大脑、心房或心室分泌的一种多肽激素，具有利尿、血管扩张、抑制肾素和醛固酮的产生以及抗心肌纤维化作用，在诊断心源性卒中方面具有较高的敏感性和特异性。其次部分心房颤动可呈间断性发作，无明显的临床症状（如阵发性、隐匿性心房颤动），临床上诊断较为困难是隐源性卒中（cryptogenic stroke，CS）的重要病因，脑钠肽与氨基末端-脑钠肽前体（N-terminal pro-brain Natriuretic Peptide，NT-proBNP）可识别心房颤动高危患者，减少需要接受心电监护的患者将隐源性卒中病因正确分类，制定更加合理的治疗方案及二级卒中预防措施。

关键词

脑钠肽；氨基末端-脑钠肽前体；心源性卒中；隐源性卒中；心房颤动

参考

[1] 马林, 巢宝华, 曹雷, et al. 2007—2017年中国脑卒中流行趋势及特征分析 [J]. 中华脑血管病杂志(电子版), 2020, 14(05): 253-8.[2] 王陇德, 吉训明, 康德智, et al. 《中国卒中中心报告2020》概要 [J]. 中国脑血管病杂志, 2021, 18(11): 737-43.[3] SUDOH T, KANGAWA K, MINAMINO N, et al. A new natriuretic peptide in porcine brain [J]. Nature, 1988, 332(6159): 78-81.[4] ABURAYA M, SUZUKI E, MINAMINO N, et al. Concentration and molecular forms of brain natriuretic peptide in rat plasma and spinal cord [J]. Biochem Biophys Res Commun, 1991, 177(1): 40-7.[5] HALL C. Essential biochemistry and physiology of (NT-pro)BNP [J]. Eur J Heart Fail, 2004, 6(3): 257-60.[6] SUGA S, NAKAO K, HOSODA K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide [J]. Endocrinology, 1992, 130(1): 229-39.[7] POTTER L R, YODER A R, FLORA D R, et al. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications [J]. Handb Exp Pharmacol, 2009, (191): 341-66.[8] TARNOW L, HILDEBRANDT P, HANSEN B V, et al. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy [J]. Diabetologia, 2005, 48(1): 149-55.[9] WALLéN T, LANDAHL S, HEDNER T, et al. Brain natriuretic peptide predicts mortality in the elderly [J]. Heart, 1997, 77(3): 264-7.[10] LINDAHL B, LINDBACK J, JERNBERG T, et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy [J]. J Am Coll Cardiol, 2005, 45(4): 533-41.[11] ADAMS H P, BENDIXEN B H, KAPPELLE L J, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment [J]. Stroke, 1993, 24(1): 35-41.[12] WU S, WU B, LIU M, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management [J]. The Lancet Neurology, 2019, 18(4): 394-405.[13] BABKAIR L A. Cardioembolic Stroke: A Case Study [J]. Crit Care Nurse, 2017, 37(1): 27-39.[14] TSAO C W, ADAY A W, ALMARZOOQ Z I, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association [J]. Circulation, 2022, 145(8): e153-e639.[15] KOLMOS M, CHRISTOFFERSEN L, KRUUSE C. Recurrent Ischemic Stroke - A Systematic Review and Meta-Analysis [J]. J Stroke Cerebrovasc Dis, 2021, 30(8): 105935.[16] 国家卫生健康委员会脑卒中防治专家委员会房颤卒中防治专业委员会, 中华医学会心电生理和起搏分会, 中国医师协会心律学专业委员会. 中国心源性卒中防治指南(2019) [J]. 中华心律失常学杂志, 2019, 23(6): 463-84.[17] CHAUDHURI J R, SHARMA V K, MRIDULA K R, et al. Association of plasma brain natriuretic peptide levels in acute ischemic stroke subtypes and outcome [J]. J Stroke Cerebrovasc Dis, 2015, 24(2): 485-91.[18] NAKAMURA M, ISHIBASHI Y, TANAKA F, et al. Ability of B-Type Natriuretic Peptide Testing to Predict Cardioembolic Stroke in the General Population- Comparisons With C-Reactive Protein and Urinary Albumin [J]. Circ J, 2018, 82(4): 1017-25.[19] BAI J, SUN H, XIE L, et al. Detection of cardioembolic stroke with B-type natriuretic peptide or N-terminal pro-BNP: a comparative diagnostic meta-analysis [J]. Int J Neurosci, 2018, 128(11): 1100-8.[20] LLOMBART V, ANTOLIN-FONTES A, BUSTAMANTE A, et al. B-type natriuretic peptides help in cardioembolic stroke diagnosis: pooled data meta-analysis [J]. Stroke, 2015, 46(5): 1187-95.[21] 赵香梅, 秦历杰, 杨先芝. NT-proBNP水平在急性缺血性脑卒中患者中的应用价值 [J]. 中华全科医学, 2020, 18(02): 177-80.[22] RASHIDI A. Mechanism of high brain natriuretic peptide in patients with atrial fibrillation [J]. Am J Cardiol, 2004, 93(5): 670.[23] GOETZE J P, BRUNEAU B G, RAMOS H R, et al. Cardiac natriuretic peptides [J]. Nat Rev Cardiol, 2020, 17(11): 698-717.[24] ROMAŃCZYK M, SURMA S, ŁABUZEK K. Natriuretic peptides in diagnostics and therapy [J]. Pol Merkur Lekarski, 2020, 48(287): 370-4.[25] ROMANENKO A V, SOLOVYEVA E Y. [Pathogenetic and therapeutic aspects of cardioembolic stroke] [J]. Zh Nevrol Psikhiatr Im S S Korsakova, 2021, 121(3): 165-72.[26] 陈利红, 张辉. 急性脑梗死患者B型脑钠肽的变化及其临床意义 [J]. 中国实用神经疾病杂志, 2018, 21(04): 424-6.[27] WANG R, WEI Y, TENG J. Levels of Plasma N-terminal Pro-brain Natriuretic Peptide and D-dimer on the Prognosis of Patients with Acute Cerebral Infarction [J]. Pak J Med Sci, 2018, 34(4): 855-8.[28] WOLF M E, GRITTNER U, BOTTCHER T, et al. Phenotypic ASCO Characterisation of Young Patients with Ischemic Stroke in the Prospective Multicentre Observational sifap1 Study [J]. Cerebrovasc Dis, 2015, 40(3-4): 129-35.[29] HART R G, DIENER H-C, COUTTS S B, et al. Embolic strokes of undetermined source: the case for a new clinical construct [J]. The Lancet Neurology, 2014, 13(4): 429-38.[30] FONSECA A C, FERRO J M. Cryptogenic stroke [J]. Eur J Neurol, 2015, 22(4): 618-23.[31] YAGHI S, BERNSTEIN R A, PASSMAN R, et al. Cryptogenic Stroke: Research and Practice [J]. Circ Res, 2017, 120(3): 527-40.[32] WASSER K, WEBER-KRUGER M, GROSCHEL S, et al. Brain Natriuretic Peptide and Discovery of Atrial Fibrillation After Stroke: A Subanalysis of the Find-AFRANDOMISED Trial [J]. Stroke, 2020, 51(2): 395-401.[33] ZHANG K, KAMTCHUM-TATUENE J, LI M, et al. Cardiac natriuretic peptides for diagnosis of covert atrial fibrillation after acute ischaemic stroke: a meta-analysis of diagnostic accuracy studies [J]. Stroke Vasc Neurol, 2021, 6(1): 128-32.[34] FONSECA A C, BRITO D, PINHO E MELO T, et al. N-terminal pro-brain natriuretic peptide shows diagnostic accuracy for detecting atrial fibrillation in cryptogenic stroke patients [J]. Int J Stroke, 2014, 9(4): 419-25.